Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study

NCT03340506 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT03340506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03340506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 4
Overall status
Recruiting
Start date
January 26, 2018
Completion date
December 28, 2032
Enrollment
100 (estimated)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

high grade glioma, melanoma, non small cell lung cancer, rare cancers, solid tumor